Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFL-PDT Laser Density for Actinic Keratosis
NCT03731988Phase 4Completed
- Sponsor
- Dong-A University
- Start
- Feb 2017
- Primary completion
- Oct 2017
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of methyl aminolevulinate in actinic keratosis (AK) (3 arms), sponsored by Dong-A University. Primary endpoints: Short-term Complete Response Rate at 3 months, Long-term Complete Response Rate at 12 months and 2 more. Started Feb 2017; status: completed.
02
Drugs
methyl aminolevulinate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT03731988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03731988.